Specifically, SS18 rearrangements involving the MEF2C and MEF2D partner genes, resulting in MEF2C::SS18 and MEF2D:SS18 gene fusions, have been identified in microsecretory adenocarcinoma and the B‐cell acute lymphoblastic leukemia, respectively. Here, MEF2D is linked to B-cell acute lymphoblastic leukemia.